Switch theme
Sign up to access all valuation multiples
CombiGene AB is a gene therapy explorer based in Sweden. The company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present. It develops gene therapies with the ambition to offer patients affected by severe life-changing diseases opportunities for a better life.
1990
8
Last FY Revenue $34K
Last FY EBITDA -$3.5M
-$2.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, CombiGene achieved revenue of $34K and an EBITDA of -$3.5M.
CombiGene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CombiGene valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $34K | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$3.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -10497% | XXX | XXX | XXX |
| EBIT | XXX | -$4.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | -14484% | XXX | XXX | XXX |
| Net Profit | XXX | -$4.6M | XXX | XXX | XXX |
| Net Margin | XXX | -13766% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CombiGene's stock price is SEK 2 (or $0).
CombiGene has current market cap of SEK 48.1M (or $5.0M), and EV of -SEK 25.6M (or -$2.6M).
See CombiGene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$2.6M | $5.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CombiGene has market cap of $5.0M and EV of -$2.6M.
CombiGene's trades at -78.6x EV/Revenue multiple, and 0.7x EV/EBITDA.
Equity research analysts estimate CombiGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CombiGene's P/E ratio is not available.
See valuation multiples for CombiGene and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.0M | XXX | $5.0M | XXX | XXX | XXX |
| EV (current) | -$2.6M | XXX | -$2.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | -78.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 0.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -1.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCombiGene's revenue per employee in the last FY averaged $4K, while opex per employee averaged $0.6M for the same period.
CombiGene's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CombiGene's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CombiGene and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -10497% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $4K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 14584% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CombiGene acquired XXX companies to date.
Last acquisition by CombiGene was XXXXXXXX, XXXXX XXXXX XXXXXX . CombiGene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CombiGene founded? | CombiGene was founded in 1990. |
| Where is CombiGene headquartered? | CombiGene is headquartered in Sweden. |
| How many employees does CombiGene have? | As of today, CombiGene has 8 employees. |
| Is CombiGene publicy listed? | Yes, CombiGene is a public company listed on STO. |
| What is the stock symbol of CombiGene? | CombiGene trades under COMBI ticker. |
| When did CombiGene go public? | CombiGene went public in 2015. |
| Who are competitors of CombiGene? | Similar companies to CombiGene include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CombiGene? | CombiGene's current market cap is $5.0M |
| Is CombiGene profitable? | Yes, CombiGene is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
